Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | CPB1 | P15086 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3744086 | 1.00 | ALDH1A1 (0.56) | ALDH1A1GAACPB1TSHRCYP1A2 | |
| SCHEMBL7114434 | 1.00 | ALDH1A1 (0.56) | ALDH1A1GAACPB1TSHRCYP1A2 | |
| SCHEMBL13198668 | 1.00 | ALDH1A1 (0.56) | ALDH1A1GAACPB1TSHRCYP1A2 | |
| SCHEMBL6027318 | 1.00 | ALDH1A1 (0.56) | ALDH1A1GAACPB1TSHRCYP1A2 | |
| SCHEMBL6182604 | 1.00 | ALDH1A1 (0.56) | ALDH1A1GAACPB1TSHRCYP1A2 | |
| SCHEMBL4261374 | 0.90 | ALDH1A1 (0.58) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL4261378 | 0.90 | ALDH1A1 (0.58) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL4083202 | 0.90 | ALDH1A1 (0.58) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL5029572 | 0.89 | TSHR (0.57) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL5029578 | 0.89 | TSHR (0.57) | ALDH1A1GAACPB1TSHREPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-20240228508-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2024-07-11 | — | — | US | disclosed |
| US-11851442-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2023-12-26 | — | — | US | disclosed |
| US-20210387998-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE HOLDINGS CORPORATION | 2021-12-16 | — | — | US | disclosed |
| US-11161855-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200040002-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2020-02-06 | — | — | US | disclosed |
| US-10370387-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180148460-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2018-05-31 | — | — | US | disclosed |
| US-9777017-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-10-03 | — | — | US | disclosed |
| US-9181271-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-11-10 | — | — | US | disclosed |
| US-20060128680-A1 | Macrocyclic module compositions | KRIESEL JOSH | 2006-06-15 | — | — | US | disclosed |
| US-20060041077-A1 | Nanofilm compositions with polymeric components | COVALENT PARTNERS LLC | 2006-02-23 | — | — | US | disclosed |
| US-20050154199-A1 | Bridged macrocyclic module compositions | COVALENT PARTNERS LLC | 2005-07-14 | — | — | US | disclosed |
| US-6914048-B2 | Method for delivery of molecules to intracellular targets | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2005-07-05 | — | — | US | disclosed |
| US-20040260085-A1 | Nanofilm and membrane compositions | COVALENT PARTNERS LLC | 2004-12-23 | — | — | US | disclosed |
| US-6683154-B1 | UNNATURAL CATIONIC OLIGOMERS THAT HAVE NO KNOWN NATURAL COUNTERPART AND THAT DISPLAY ANTIBIOTIC ACTIVITY COMPARABLE TO THAT OF MAGAININ DERIVATIVE AGAINST AT LEAST FOUR DIFFERENT BACTERIAL SPECIES, YET EXHIBIT LOWER HEMOLYTIC ACTIVITY | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-01-27 | — | — | US | disclosed |
| US-6613876-B1 | Covalently linking subunit of given formula to a plurality of separable solid substrates; deprotecting; used for generating combinatorial libraries | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-09-02 | — | — | US | disclosed |
| US-20030119189-A1 | Method for delivery of molecules to intracellular targets | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-06-26 | — | — | US | disclosed |
| US-20020037997-A1 | Beta-amino acids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-03-28 | — | — | US | disclosed |
| US-6060585-A | β-polypeptide foldamers of well-defined secondary structure | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2000-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228508-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | ALDH1A1 4431/4885GAA 4144/4885CPB1 3695/4885 |
| US-20200040002-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | ALDH1A1 4431/4885GAA 4144/4885CPB1 3695/4885 |
| US-20180148460-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | ALDH1A1 4431/4885GAA 4144/4885CPB1 3695/4885 |
| US-20030119189-A1 | Method for delivery of molecules to intracellular targets | DNPEP, SLC7A1, PHAX | ALDH1A1 3895/4885GAA 628/4885CPB1 634/4885 |
| US-11851442-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | JAK1, JAK3, JAK2 | ALDH1A1 4431/4885GAA 4144/4885CPB1 3695/4885 |
| US-11161855-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | JAK1, JAK3, JAK2 | ALDH1A1 4431/4885GAA 4144/4885CPB1 3695/4885 |
| US-20050154199-A1 | Bridged macrocyclic module compositions | SBDS, NCL, INTS6 | ALDH1A1 3961/4885GAA 2779/4885CPB1 1631/4885 |
| US-20060128680-A1 | Macrocyclic module compositions | CYCS, IMMT, INTS9 | ALDH1A1 4880/4885GAA 3676/4885CPB1 1455/4885 |
| US-20040260085-A1 | Nanofilm and membrane compositions | CLPTM1, APMAP, PHOSPHO1 | ALDH1A1 4428/4885GAA 1352/4885CPB1 3722/4885 |
| US-10370387-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | JAK1, JAK3, JAK2 | ALDH1A1 4431/4885GAA 4144/4885CPB1 3695/4885 |
| US-20020037997-A1 | Beta-amino acids | BCAT1, BCAT2, MARCKS | ALDH1A1 4863/4885GAA 3570/4885CPB1 200/4885 |
| US-20210387998-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | ALDH1A1 4431/4885GAA 4144/4885CPB1 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.